Travere Therapeutics (TVTX) PT Lowered to $42 at Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity analyst Edward Nash lowered the price target on Travere Therapeutics (NASDAQ: TVTX) to $42.00 (from $45.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
